Durable efficacy of frontline zanubrutinib in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) in patients with del(17p): Extended median follow-up of SEQUOIA Arm C

ASH 2026 • CLL/SLL • Zanubrutinib • Poster

Constantine S. Tam, MBBS MD FRACP FRCPA

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

SEQUOIA arm C was a prospective nonrandomized phase 3 cohort evaluating zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma harboring del(17p). This analysis reported the updated outcomes from arm C after extended median follow-up (mFU), and for the first time, characterized outcomes with subsequent therapy after zanubrutinib discontinuation in this high-risk population. Arm C enrolled 111 patients, including 110 with confirmed del(17p). TP53 mutation, unmutated immunoglobulin heavy-chain variable region (IGHV), and complex karyotype (≥3 chromosomal abnormalities) were present in 47 (42.3%), 67 (60.4%), and 31 (27.9%) patients, respectively. At a mFU of 87.6 months (range, 5.0-98.4 months), the estimated progression-free survival (PFS) rate at 78 months was 59.3% (95% CI, 48.9-68.3) and 60.0% (95% CI, 49.5-69.0) after adjustment for COVID-19. Estimated 78-month overall survival (OS) and time to second progression event or death (PFS2) rates were 78.3% (95% CI, 69.2-85.0) and 78.4% (95% CI, 69.2-85.1), respectively. Among individuals who received subsequent anti-CLL therapy (n=27), most (n=18) received a B-cell lymphoma 2 (BCL2) inhibitor-based treatment. After an mFU of 26 months from BCL2 inhibitor initiation, the estimated 2-year PFS rate was 58.7% (95% CI, 28.3-79.8). A total of 30 patients (27.0%) died, most commonly due to progressive disease (n=11, 9.9%) and adverse events (AEs; n=9, 8.1%), including two deaths (1.8%) that were considered treatment related. Grade ≥3 AEs of special interest included infections (34.2%), hypertension (10.8%), second primary malignancies excluding non-melanoma skin cancers (9.9%), hemorrhage (8.1%), and atrial fibrillation/flutter (5.4%).

ClinicalTrials.gov ID: NCT03336333

Population Intervention / Exposure Comparator Outcomes
Patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma and centrally confirmed del(17p) who were aged ≥65 years and/or unsuitable for fludarabine, cyclophosphamide, and rituximab–based chemoimmunotherapy Zanubrutinib N/A Progression-free survival, time to next treatment, time to next treatment or death, time to second progression event or death, overall survival, safety, and outcomes with subsequent therapies following zanubrutinib discontinuation

FAQs

The study evaluated long-term efficacy, safety, survival outcomes, and outcomes following subsequent therapy in patients with treatment-naïve chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) and del(17p) receiving zanubrutinib in SEQUOIA arm C.

This was a prospective, nonrandomized cohort study of patients with treatment-naïve CLL/SLL and centrally confirmed del(17p) who were aged ≥65 years and/or unsuitable for fludarabine, cyclophosphamide, and rituximab–based chemoimmunotherapy. Patients received zanubrutinib 160 mg twice a day until progressive disease (PD) or unacceptable toxicity. Endpoints included progression-free survival (PFS), time to next treatment (TTNT), time to next treatment or death (TTNT-D), time to second progression event or death (PFS2), overall survival (OS), safety, and outcomes following subsequent therapies. Adverse events (AEs) were monitored until PD or initiation of next-line therapy. PFS, PFS2, and OS analyses were also adjusted for COVID-19-related mortality.

The study enrolled 111 patients, of whom 110 had confirmed del(17p). At baseline, TP53 mutation, unmutated immunoglobulin heavy-chain variable region (IGHV), and complex karyotype (≥3 chromosomal abnormalities) were observed in 42.3%, 60.4%, and 27.9% of patients, respectively, with a median age of 71 years (range, 42-87). After a median follow-up of 87.6 months (range, 5.0-98.4 months), 49 patients (44.1%) remained on zanubrutinib. Among those who discontinued, the most common reasons were AEs (26.1%) and PD (20.7%).

At 78 months, the estimated PFS rate was 59.3% (95% CI, 48.9-68.3), or 60.0% (95% CI, 49.5-69.0) after adjustment for COVID-19. Consistent efficacy was observed regardless of IGHV status (estimated 78-month PFS rates: unmutated IGHV, 58.3% [95% CI, 44.5-69.8]; mutated IGHV, 62.6% [95% CI, 44.3-76.4]). Estimated TTNT and TTNT-D rates at 78 months were 78.0% (95% CI, 68.4-84.9) and 67.2% (95% CI, 57.3-75.2), respectively. Estimated 78-month PFS2 and OS rates were 78.4% (95% CI, 69.2-85.1) and 78.3% (95% CI, 69.2-85.0), respectively, with COVID-19-adjusted estimates of 80.1% (95% CI, 71.0-86.5) and 80.0% (95% CI, 71.0-86.5), respectively.

Among 27 patients (24.5%) who received subsequent anti-CLL therapy, 25 did so following PD. Of these, 18 patients received a B-cell lymphoma 2 (BCL-2) inhibitor-based regimen, five received chemoimmunotherapy, and two received a covalent/non-covalent Bruton tyrosine kinase inhibitor. After a median follow-up of 26 months from initiation of BCL-2 inhibitor-based therapy, 11 of 18 patients remained alive and progression-free, with an estimated 2-year PFS rate of 58.7% (95% CI, 28.3-79.8).

A total of 30 patients (27.0%) died, most commonly due to PD (n=11 [9.9%]) and AEs (n=9 [8.1%]), including two deaths (1.8%) that were considered treatment related. Grade ≥3 AEs of special interest (% of patients; exposure-adjusted incidence rate per 100 person-months) included infections (34.2%; 0.64), hypertension (10.8%; 0.18), second primary malignancies excluding non-melanoma skin cancers (9.9%; 0.16), hemorrhage (8.1%; 0.13), and atrial fibrillation/flutter (5.4%; 0.08).

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed